Premier Anti-Aging Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Kiyoshi Matsuura

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	14.9yrs
CEO sahipliği	67.1%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

Little Excitement Around Premier Anti-Aging Co., Ltd.'s (TSE:4934) Revenues As Shares Take 30% Pounding

Aug 06

Premier Anti-Aging (TSE:4934) Has Debt But No Earnings; Should You Worry?

Mar 04

CEO

Kiyoshi Matsuura (56 yo)

14.9yrs

Görev süresi

Mr. Kiyoshi Matsuura has been the Representative Director and President of Premier Anti-Aging Co., Ltd. since December 2009.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kiyoshi Matsuura	President & Representative Director	no data	Veri yok	67.15% ¥ 4.2b
Yoichiro Ito	Director	2.1yrs	Veri yok	0.055% ¥ 3.5m
Motoyasu Ishihara	Full Time Auditor	3.9yrs	Veri yok	0.031% ¥ 1.9m
Akira Ide	Outside Auditor	3yrs	Veri yok	0.010% ¥ 648.0k
Yosuke Kondo	Outside Auditor	5.2yrs	Veri yok	0.011% ¥ 720.2k
Sakiko Sakai	Outside Independent Director	4.3yrs	Veri yok	0.010% ¥ 648.0k

3.9yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4934 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Premier Anti-Aging Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Premier Anti-Aging Co., Ltd., Annual General Meeting, Oct 29, 2024

Premier Anti-Aging Co., Ltd., Annual General Meeting, Oct 27, 2023

Recent updates

Premier Anti-Aging Co., Ltd. to Report Q1, 2025 Results on Dec 13, 2024

Premier Anti-Aging Co., Ltd. Announces Renewal of DUO the Cleansing Balm Series

New major risk - Financial data availability

Full year 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Premier Anti-Aging Co., Ltd., Annual General Meeting, Oct 29, 2024

Little Excitement Around Premier Anti-Aging Co., Ltd.'s (TSE:4934) Revenues As Shares Take 30% Pounding

New minor risk - Share price stability

Premier Anti-Aging Co., Ltd. to Report Fiscal Year 2024 Results on Sep 12, 2024

Consensus EPS estimates upgraded to JP¥240 loss

Third quarter 2024 earnings released: EPS: JP¥26.95 (vs JP¥14.56 loss in 3Q 2023)

New minor risk - Share price stability

Price target decreased by 28% to JP¥760

Consensus EPS estimates fall by 65%

Premier Anti-Aging Co., Ltd. to Report Q3, 2024 Results on Jun 13, 2024

Second quarter 2024 earnings released: JP¥189 loss per share (vs JP¥19.72 profit in 2Q 2023)

Premier Anti-Aging (TSE:4934) Has Debt But No Earnings; Should You Worry?

Consensus EPS estimates fall by 10%

Premier Anti-Aging Co., Ltd. to Report Q2, 2024 Results on Mar 14, 2024

First quarter 2024 earnings released: JP¥4.01 loss per share (vs JP¥22.71 loss in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Premier Anti-Aging Co., Ltd. to Report Q1, 2024 Results on Dec 14, 2023

Full year 2023 earnings: EPS misses analyst expectations

Premier Anti-Aging Co., Ltd. Provides Consolidated Earning Guidance for the Six Months Ending January 31, 2024 and Full Year Ending July 31, 2024

Premier Anti-Aging Co., Ltd., Annual General Meeting, Oct 27, 2023

New major risk - Share price stability

Premier Anti-Aging Co., Ltd. to Report Fiscal Year 2023 Results on Sep 14, 2023

Third quarter 2023 earnings released: JP¥14.56 loss per share (vs JP¥15.83 loss in 3Q 2022)

Premier Anti-Aging Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending July 31, 2023

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥19.72 (vs JP¥4.59 in 2Q 2022)

Premier Anti-Aging Co., Ltd. (TSE:4934) completed the acquisition of Venex Co., Ltd from Taichi Nakamura and other shareholders.

Premier Anti-Aging Co., Ltd. to Report Q2, 2023 Results on Mar 14, 2023

Premier Anti-Aging Co., Ltd. (TSE:4934) agreed to acquire Venex Co., Ltd from Taichi Nakamura and other shareholders.

Price target decreased to JP¥1,880

Premier Anti-Aging Co., Ltd. Provides Earning Guidance for the Six Months Ending January 31, 2023 and Full Year Ending July 31, 2023

Premier Anti-Aging Co., Ltd. to Report Q1, 2023 Results on Dec 14, 2022

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 11%

Premier Anti-Aging Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended January 31, 2023 and Fiscal Year Ended July 31, 2023

Now 21% undervalued after recent price drop

Premier Wellness Science Co., Ltd. to Launch a New Brand "Reinca"

Premier Wellness Science Co., Ltd. to Launch a New Brand "Reinca"

Investor sentiment improved over the past week

Premier Anti-Aging Co., Ltd. to Report Fiscal Year 2022 Results on Sep 13, 2022

Premier Anti-Aging Co., Ltd.’s Consolidated Subsidiary Premier Wellness Sciences Co., Ltd. Announces the Launch of Its New Brand "Ko" with CBD

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Premier Anti-Aging Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending July 31, 2022

Price target decreased to JP¥5,060

Premier Anti-Aging Co., Ltd. to Report Q3, 2022 Results on Jun 13, 2022

Investor sentiment improved over the past week

Consensus EPS estimates fall by 11%

Investor sentiment deteriorated over the past week

Premier Anti-Aging Co., Ltd. to Report Q2, 2022 Results on Mar 14, 2022

Price target decreased to JP¥14,330

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: JP¥9,410

Premier Anti-Aging Co., Ltd. to Report Q2, 2021 Results on Mar 15, 2021

Premier Anti-Aging Co., Ltd. to Report Q1, 2021 Results on Dec 14, 2020

Premier Anti-Aging Co., Ltd. has completed an IPO in the amount of ¥9.729 billion.

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş